Amphotericin B releasing nanoparticle topical treatment of Candida spp. in the setting of a burn wound

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 1, 2014, Pages 269-277

  Sanchez, David A ^a   Schairer, David ^a   Tuckman Vernon, Chaim ^a   Chouake, Jason ^a   Kutner, Allison ^a   Makdisi, Joy ^a   Friedman, Joel M ^a   Nosanchuk, Joshua D ^a   Friedman, Adam J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Amphotericin B; Burn wounds; Candida spp.; Nanoparticles; Topical antifungal

Indexed keywords

AMPHOTERICIN B; ANTI-FUNGAL; BURN WOUNDS; CANDIDA SPP; CLINICAL STRAINS; GROWTH REDUCTION; METABOLIC ACTIVITY; TOPICAL TREATMENTS;

NANOPARTICLES; SOLS; YEAST;

CANDIDA;

AMPHOTERICIN B; FLUCONAZOLE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL VIABILITY; BIOFILM; BURN; BURN INFECTION; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDIASIS; CELL VIABILITY ASSAY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; EPITHELIZATION; FUNGAL CELL; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; GRANULATION TISSUE; GROWTH INHIBITION; HYPOTHESIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SYNTHESIS; WOUND HEALING; XTT ASSAY;

CANDIDA; MURINAE;

AMPHOTERICIN B; BURN WOUNDS; CANDIDA SPP.; NANOPARTICLES; TOPICAL ANTIFUNGAL;

ADMINISTRATION, TOPICAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BURNS; CANDIDA; HUMANS; MICE; NANOPARTICLES; WOUNDS AND INJURIES;

EID: 84890983286     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.06.002     Document Type: Article

References (33)

1. Branski L.K., Al-Mousawi A., Rivero H., Jeschke M.G., Sanford A.P., Herndon D.N. Emerging infections in burns. Surg Infect (Larchmt). 2009, 10(5):389-397. [PubMed PMID: 19810827. Pubmed Central PMCID: 2956561. Epub 2009/10/09. eng].
2. Sarabahi S., Tiwari V.K., Arora S., Capoor M.R., Pandey A. Changing pattern of fungal infection in burn patients. Burns 2012, 38(4):520-528. [PubMed PMID: 22035885. Epub 2011/11/01. eng].
3. Horvath E.E., Murray C.K., Vaughan G.M., Chung K.K., Hospenthal D.R., Wade C.E., et al. Fungal wound infection (not colonization) is independently associated with mortality in burn patients. Ann Surg 2007, 245(6):978-985. [PubMed PMID: 17522525. Pubmed Central PMCID: 1876957. Epub 2007/05/25. eng].
4. Sobral C.S., Gragnani A., Morgan J., Ferreira L.M. Inhibition of proliferation of Pseudomonas aeruginosa by KGF in an experimental burn model using human cultured keratinocytes. Burns 2007, 33(5):613-620. [PubMed PMID: 17418954. Epub 2007/04/10. eng].
5. Santucci S.G., Gobara S., Santos C.R., Fontana C., Levin A.S. Infections in a burn intensive care unit: experience of seven years. J Hosp Infect 2003, 53(1):6-13. [PubMed PMID: 12495679. Epub 2002/12/24. eng.].
6. Church D., Elsayed S., Reid O., Winston B., Lindsay R. Burn wound infections. Clin Microbiol Rev 2006, 19(2):403-434. [PubMed PMID: 16614255. Pubmed Central PMCID: 1471990, Epub 2006/04/15. eng.].
7. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317. [PubMed PMID: 15306996. Epub 2004/08/13. eng].
8. Holzheimer R.G., Dralle H. Management of mycoses in surgical patients - review of the literature. Eur J Med Res 2002, 7(5):200-226. [PubMed PMID: 12069912. Epub 2002/06/19. eng].
9. Krcmery V., Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002, 50(4):243-260. [PubMed PMID: 12014897. Epub 2002/05/17. eng].
10. Wurtz R., Karajovic M., Dacumos E., Jovanovic B., Hanumadass M. Nosocomial infections in a burn intensive care unit. Burns 1995, 21(3):181-184. [PubMed PMID: 7794498. Epub 1995/05/01. eng].
11. Blyth D.M., Chung K.K., Cancio L.C., King B.T., Murray C.K. Clinical utility of fungal screening assays in adults with severe burns. Burns 2012, [PubMed PMID: 22999208. Epub 2012/09/25. Eng].
12. Karimzadeh I., Farsaei S., Khalili H., Dashti-Khavidaki S. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicityα. Expert Opin Drug Saf 2012, [PubMed PMID: 22950480. Epub 2012/09/07. Eng].
13. Atiyeh B.S., Gunn S.W., Hayek S.N. State of the art in burn treatment. World J Surg 2005, 29(2):131-148. [PubMed PMID: 15654666. Epub 2005/01/18. eng].
14. Cabrales P., Han G., Roche C., Nacharaju P., Friedman A.J., Friedman J.M. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic Biol Med 2010, 49(4):530-538. [PubMed PMID: 20460149. Pubmed Central PMCID: 2903640. Epub 2010/05/13. eng.].
15. Friedman A.J., Han G., Navati M.S., Chacko M., Gunther L., Alfieri A., et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide 2008, 19(1):12-20. [PubMed PMID: 18457680. Epub 2008/05/07. eng].
16. Macherla C., Sanchez D.A., Ahmadi M.S., Vellozzi E.M., Friedman A.J., Nosanchuk J.D., et al. Nitric oxide releasing nanoparticles for treatment of Candida albicans burn infections. Front Microbiol. 2012, 3:193. [PubMed PMID: 22701111. Pubmed Central PMCID: 3370663. Epub 2012/06/16. eng.].
17. Rex JH. Reference Method for Broth Dilution Antifungal Yeast Susceptibility Testing of Yeast; Approved Standard-Third Edition. Clinical and Laboratory Standards Institute [Internet]. 2008 M27-A3; 28.
18. Martinez L.R., Mihu M.R., Han G., Frases S., Cordero R.J., Casadevall A., et al. The use of chitosan to damage Cryptococcus neoformans biofilms. Biomaterials 2010, 31(4):669-679. [PubMed PMID: 19819009. Pubmed Central PMCID: PMC2783412. Epub 2009/10/13. eng.].
19. Meshulam T., Levitz S.M., Christin L., Diamond R.D. A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT). J Infect Dis 1995, 172(4):1153-1156. [PubMed PMID: 7561202. Epub 1995/10/01. eng].
20. Blecher K., Martinez L.R., Tuckman-Vernon C., Nacharaju P., Schairer D., Chouake J., et al. Nitric oxide-releasing nanoparticles accelerate wound healing in NOD-SCID mice. Nanomedicine 2012, 8(8):1364-1371. [PubMed PMID: 22406184. Epub 2012/03/13. eng].
21. Martinez L.R., Mihu M.R., Tar M., Cordero R.J., Han G., Friedman A.J., et al. Demonstration of antibiofilm and antifungal efficacy of chitosan against Candidal biofilms, using an in vivo central venous catheter model. J Infect Dis 2010, 201(9):1436-1440. [PubMed PMID: 20331379. Epub 2010/03/25. eng.].
22. Mihu M.R., Sandkovsky U., Han G., Friedman J.M., Nosanchuk J.D., Martinez L.R. The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections. Virulence 2010, 1(2):62-67. [PubMed PMID: 21178416. Epub 2010/12/24. eng].
23. Blecher K., Nasir A., Friedman A. The growing role of nanotechnology in combating infectious disease. Virulence 2011, 2(5):395-401. [PubMed PMID: 21921677. Epub 2011/09/17. eng].
24. Ghannoum M.A., Chen A., Buhari M., Chandra J., Mukherjee P.K., Baxa D., et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect 2009, 15(3):274-279. [PubMed PMID: 19210699. Epub 2009/02/13. eng].
25. Gupta N., Haque A., Lattif A.A., Narayan R.P., Mukhopadhyay G., Prasad R. Epidemiology and molecular typing of Candida isolates from burn patients. Mycopathologia 2004, 158(4):397-405. [PubMed PMID: 15630548. Epub 2005/01/05. eng.].
26. Kennedy P., Brammah S., Wills E. Burns, biofilm and a new appraisal of burn wound sepsis. Burns 2010, 36(1):49-56. [PubMed PMID: 19523770. Epub 2009/06/16. eng.].
27. Escamez M.J., Garcia M., Larcher F., Meana A., Munoz E., Jorcano J.L., et al. An in vivo model of wound healing in genetically modified skin-humanized mice. J Invest Dermatol 2004, 123(6):1182-1191. [PubMed PMID: 15610532. Epub 2004/12/22. eng].
28. Ghannoum M.A., Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999, 12(4):501-517. [PubMed PMID: 10515900. Pubmed Central PMCID: 88922. Epub 1999/10/09. eng].
29. Parmeland L., Gazon M., Guerin C., Argaud L., Lehot J.J., Bastien O., et al. Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade. Med Mycol 2012, [PubMed PMID: 22680978. Epub 2012/06/12. Eng.].
30. Cannon R.D., Lamping E., Holmes A.R., Niimi K., Tanabe K., Niimi M., et al. Candida albicans drug resistance another way to cope with stress. Microbiology 2007, 153(Pt 10):3211-3217. [PubMed PMID: 17906120. Epub 2007/10/02. eng].
31. Volmer A.A., Szpilman A.M., Carreira E.M. Synthesis and biological evaluation of amphotericin B derivatives. Nat Prod Rep 2010, 27(9):1329-1349. [PubMed PMID: 20556271. Epub 2010/06/18. eng].
32. Gray K.C., Palacios D.S., Dailey I., Endo M.M., Uno B.E., Wilcock B.C., et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A 2012, 109(7):2234-2239. [PubMed PMID: 22308411. Pubmed Central PMCID: 3289339. Epub 2012/02/07. eng].
33. Yildirimer L., Thanh N.T., Loizidou M., Seifalian A.M. Toxicology and clinical potential of nanoparticles. Nano Today 2011, 6(6):585-607. [PubMed PMID: 23293661. Pubmed Central PMCID: 3533686. Epub 2013/01/08. Eng].